{
    "clinical_study": {
        "@rank": "126125", 
        "acronym": "PMB/T2D", 
        "arm_group": [
            {
                "arm_group_label": "Pre-meal protein drink", 
                "arm_group_type": "Experimental", 
                "description": "A dose of 100 ml is taken just before breakfast, lunch and dinner."
            }, 
            {
                "arm_group_label": "Water drink", 
                "arm_group_type": "Placebo Comparator", 
                "description": "A dose of 100 ml is taken just before breakfast, lunch and dinner."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate if a pre-meal drink containing proteins can\n      positively influence glycaemic control in patients with type 2 diabetes mellitus. Comparison\n      with a placebo is included."
        }, 
        "brief_title": "Pre-meal Protein Drink Improve Glycemic Regulation", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  diagnosed type 2 diabetes mellitus according to WHO criteria (1999)\n\n          -  age between 30-80 years\n\n          -  non well controlled diabetes with HbA1c-levels above 62 mmol/mol\n\n        Exclusion Criteria:\n\n          -  pregnant or risk of becoming pregnant\n\n          -  severe disease\n\n          -  psychological disease, dementia or mental disability that makes it impossible to\n             retrieve informed consent of participation\n\n          -  liver disease\n\n          -  kidney malfunction (GFR <60 or aspartate transaminase (ASAT)/alanine transaminase\n             (ALT) two times higher than the normal interval"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01987674", 
            "org_study_id": "Dnr2013/239-31PMB"
        }, 
        "intervention": [
            {
                "arm_group_label": "Pre-meal protein drink", 
                "intervention_name": "Pre-meal protein drink", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Water drink", 
                "intervention_name": "Water drink", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 12, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kalmar", 
                    "country": "Sweden", 
                    "zip": "39365"
                }, 
                "name": "Lindsdals h\u00e4lsocentral"
            }
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "2", 
        "official_title": "Impact of a Pre-meal Protein Drink on Metabolic Markers and Glycemic Control in Patients With Type 2 Diabetes", 
        "other_outcome": {
            "description": "HOMA-IR is a mathematical modelling of insulin resistance using fasting values of blood glucose and serum insulin.", 
            "measure": "Homeostasis model assessment of insulin resistance (HOMA-IR)", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Sweden: Regional Ethical Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Glycated hemoglobin", 
            "measure": "HbA1c", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01987674"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Lund University", 
            "investigator_full_name": "Elin \u00d6stman", 
            "investigator_title": "Associate professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Meal challenge given at start and end of study with repeated blood glucose sampling over 2h.", 
            "measure": "Postprandial glycemia", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "source": "Lund University", 
        "sponsors": {
            "collaborator": {
                "agency": "Landstinget i Kalmar L\u00e4n", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Lund University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}